Suzanne L cialis 20mg . Topalian, M.D., F. Stephen Hodi, M.D., Julie R. Brahmer, M.D., Scott N. Gettinger, M.D., David C. Smith, M.D., David F. McDermott, M.D., John D. Powderly, M.D., Richard D. Carvajal, M.D., Jeffrey A. Sosman, M.D., Michael B. Atkins, M.D., Philip D. Leming, M.D., David R. Spigel, M.D., Scott J. Antonia, M.D., Ph.D., Leora Horn, M.D., Charles G. Drake, M.D., Ph.D., Drew M. Pardoll, M.D., Ph.D., Lieping Chen, M.D., Ph.D., William H. Sharfman, M.D., Robert A. Anders, M.D., Ph.D., Janis M. Taube, M.D., Tracee L. McMiller, M.S., Haiying Xu, B.A., Alan J. Korman, Ph.D., Maria Jure-Kunkel, Ph.D., Shruti Agrawal, Ph.D., Daniel McDonald, M.B.A., Georgia D.
These findings claim that the current presence of HLA-B*13:01 had a sensitivity of 85.5 percent and a specificity of 85.7 percent as a risk predictor for the dapsone hypersensitivity syndrome, with an certain area under the curve of 0.89 . According to these results, the risk among persons carrying one copy of the HLA-B*13:01 allele is 33.6 times as high as the chance among those carrying no copies and the risk among individuals carrying two copies is 100.7 times as high . Based on an estimated prevalence of the dapsone hypersensitivity syndrome of just one 1.4 percent,8 we calculated that HLA-B*13:01 could have a positive predictive value of 7.8 percent and a negative predictive value of 99.8 percent, and 84 sufferers would have to be screened in order to prevent one case of the syndrome.